Related Experiment Video
Updated: Feb 25, 2026
11:15
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
8.5K
Anti-GD2 immunotherapy for neuroblastoma
1a Department of Pediatrics , Memorial Sloan Kettering Cancer Center , New York , NY , USA.
Expert Review of Anticancer Therapy
|August 8, 2017
Summary
Immunotherapy targeting GD2 shows promise for high-risk neuroblastoma (HR-NB), improving survival with fewer toxicities. Novel strategies and combinations are under investigation to optimize treatment for HR-NB patients.
Area of Science:
- Oncology
- Immunology
Background:
- Current high-risk neuroblastoma (HR-NB) treatments like chemotherapy, surgery, and radiotherapy cause significant toxicities.
- Immunotherapy offers a promising alternative to improve survival and quality of life by reducing cytotoxic agent exposure.
Purpose of the Study:
- To review the current clinical status of anti-GD2 immunotherapies for neuroblastoma.
- To explore novel GD2-targeted strategies in preclinical development for HR-NB.
Main Methods:
- Review of existing literature on anti-GD2 immunotherapies in clinical use.
- Analysis of preclinical data for novel GD2-targeted strategies.
Main Results:
- Anti-GD2 monoclonal antibodies improve survival in patients in first remission and are used for refractory/relapsed neuroblastoma.
- Emerging strategies include engineered antibodies, natural killer cells, T-cells, and anti-GD2 vaccines.
Conclusions:
- Anti-GD2 immunotherapies are effective for HR-NB, with ongoing advancements in antibody engineering and cellular therapies.
- Further research is needed to optimize combinations of immunotherapies and conventional treatments for HR-NB.
